FY2025 EPS Forecast for Olema Pharmaceuticals Cut by Analyst

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at Lifesci Capital lowered their FY2025 earnings per share (EPS) estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($2.28) for the year, down from their previous estimate of ($2.12). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share.

Several other research firms also recently issued reports on OLMA. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday. Oppenheimer restated an “outperform” rating and set a $25.00 price objective (down from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday.

Olema Pharmaceuticals Stock Up 2.7 %

OLMA stock opened at $4.23 on Friday. Olema Pharmaceuticals has a 52-week low of $3.94 and a 52-week high of $16.62. The stock’s 50 day moving average is $5.09 and its two-hundred day moving average is $8.33. The company has a market capitalization of $242.37 million, a PE ratio of -1.93 and a beta of 2.11.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.12.

Insider Activity at Olema Pharmaceuticals

In other news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the transaction, the insider now owns 7,800,000 shares in the company, valued at approximately $44,928,000. The trade was a 4.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 19.40% of the company’s stock.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in OLMA. JPMorgan Chase & Co. grew its stake in Olema Pharmaceuticals by 658.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock worth $2,162,000 after buying an additional 157,171 shares during the last quarter. Victory Capital Management Inc. grew its stake in Olema Pharmaceuticals by 9.9% during the 3rd quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock worth $10,167,000 after buying an additional 76,720 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in Olema Pharmaceuticals by 80.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company’s stock worth $1,237,000 after buying an additional 94,651 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Olema Pharmaceuticals by 168.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock worth $3,949,000 after buying an additional 207,565 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Olema Pharmaceuticals by 10.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after buying an additional 97,428 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.